Keywords: Eli Lilly, Fourth-quarter and full year 2011 financial results

Eli Lilly results hammered by Zyprexa patent loss

Article | 1 February 2012

Print This

US drug major Eli Lilly (NYSE: LLY) said that fourth-quarter 2011 global sales dropped 2% to $6.05 billion. This fall in revenue was ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in